Independent directory Public ClinicalTrials.gov records United States
ClinicalTrials.gov record
Terminated Phase 4 Interventional Results available

Study to Evaluate the Efficacy and Safety of the Combination of Valturna and Amlodipine or Valturna and Chlorthalidone Versus Valturna Alone in Patients With Stage 2 Hypertension and Diabetes

ClinicalTrials.gov ID: NCT01368536

Public ClinicalTrials.gov record NCT01368536. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.

ClinicalTrials.gov public records Last synced May 6, 2026, 8:37 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Official title

A 12-week, Multi-Center, Randomized Double-Blind, Active Control Parallel Group Study to Evaluate the Efficacy and Safety of the Combination of Valturna and Amlodipine or Valturna and Chlorthalidone Versus Valturna Alone in Patients With Stage 2 Hypertension and Diabetes

Study identification

NCT ID
NCT01368536
Recruitment status
Terminated
Study type
Interventional
Phase
Phase 4
Lead sponsor
Novartis Pharmaceuticals
Industry
Enrollment
975 participants

Conditions and interventions

Interventions

  • Amlodipine Drug
  • Chlorthalidone Drug
  • Placebo Capsule Drug
  • Placebo of Valturna Tablet Drug
  • Valturna Drug

Drug

Eligibility (public fields only)

Age range
18 Years and older
Sex
All
Healthy volunteers
Healthy volunteers not accepted

This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.

Study timeline

Start date
Apr 30, 2011
Primary completion
Jan 31, 2012
Completion
Jan 31, 2012
Last update posted
Mar 20, 2013

2011 – 2012

United States locations

U.S. sites
95
U.S. states
30
U.S. cities
81
Facility City State ZIP Site status
Novartis Investigative Site Athens Alabama 35611
Novartis Investigative Site Florence Alabama 35630
Novartis Investigative Site Huntsville Alabama 35801
Novartis Investigative Site Montgomery Alabama 36106
Novartis Investigative Site Muscle Shoals Alabama 35662
Novartis Investigative Site Chandler Arizona 85224
Novartis Investigative Site Little Rock Arkansas 72204
Novartis Investigative Site Buena Park California 90620
Novartis Investigative Site Fair Oaks California 95628
Novartis Investigative Site Fresno California 93726
Novartis Investigative Site Healdsburg California 95448
Novartis Investigative Site Los Angeles California 90057
Novartis Investigative Site Orangevale California 95662
Novartis Investigative Site Riverside California 92506
Novartis Investigative Site Roseville California 95661
Novartis Investigative Site Sacramento California 95816
Novartis Investigative Site Santa Ana California 92701
Novartis Investigative Site West Covina California 91790
Novartis Investigative Site Shelton Connecticut 06484
Novartis Investigative Site Fort Lauderdale Florida 33306
Novartis Investigative Site Fort Lauderdale Florida 33308
Novartis Investigative Site Jupiter Florida 33458
Novartis Investigative Site Lauderdale Lakes Florida 33319
Novartis Investigative Site North Miami Beach Florida 33169
Novartis Investigative Site St. Petersburg Florida 33701
Novartis Investigative Site Tampa Florida 33603
Novartis Investigative Site West Palm Beach Florida 33409
Novartis Investigative Site Augusta Georgia 30904
Novartis Investigative Site Honolulu Hawaii 96813
Novartis Investigative Site Chicago Illinois 60607
Novartis Investigative Site Chicago Illinois 60610
Novartis Investigative Site Chicago Illinois 60617
Novartis Investigative Site Gurnee Illinois 60031
Novartis Investigative Site Lansing Kansas 66043
Novartis Investigative Site Topeka Kansas 66606
Novartis Investigative Site Beltsville Maine 20705
Novartis Investigative Site Waltham Massachusetts 02453
Novartis Investigative Site Wellesley Hills Massachusetts 02481-2106
Novartis Investigative Site Brooklyn Center Minnesota 55430-2168
Novartis Investigative Site Belzoni Mississippi 39038
Novartis Investigative Site Jackson Mississippi 39209
Novartis Investigative Site Picayune Mississippi 39466
Novartis Investigative Site Kansas City Missouri 64111
Novartis Investigative Site Ozark Missouri 65721
Novartis Investigative Site St Louis Missouri 63110-1093
Novartis Investigative Site St Louis Missouri 63128
Novartis Investigative Site St Louis Missouri 63141
Novartis Investigative Site Omaha Nebraska 68134
Novartis Investigative Site Henderson Nevada 89014
Novartis Investigative Site Las Vegas Nevada 89119
Novartis Investigative Site Toms River New Jersey 08753
Novartis Investigative Site Toms River New Jersey 08755
Novartis Investigative Site Trenton New Jersey 08629
Novartis Investigative Site Buffalo New York 14209
Novartis Investigative Site Camillus New York 13031
Novartis Investigative Site Asheboro North Carolina 27204
Novartis Investigative Site Asheville North Carolina 28801
Novartis Investigative Site Greensboro North Carolina 27401
Novartis Investigative Site Greensboro North Carolina 27408
Novartis Investigative Site Shelby North Carolina 28150
Novartis Investigative Site Winston-Salem North Carolina 27103
Novartis Investigative Site Fargo North Dakota 58103
Novartis Investigative Site Cincinnati Ohio 45219
Novartis Investigative Site Cincinnati Ohio 45224
Novartis Investigative Site Columbus Ohio 43201
Novartis Investigative Site Lyndhurst Ohio 44124
Novartis Investigative Site Zanesville Ohio 43701
Novartis Investigative Site Oklahoma City Oklahoma 73132-4904
Novartis Investigative Site Oklahoma City Oklahoma 73134
Novartis Investigative Site Portland Oregon 97232
Novartis Investigative Site Reading Pennsylvania 19609
Novartis Investigative Site Uniontown Pennsylvania 15401
Novartis Investigative Site Wallingford Pennsylvania 19086
Novartis Investigative Site Charleston South Carolina 29407
Novartis Investigative Site Charleston South Carolina 29412
Novartis Investigative Site Easley South Carolina 29640
Novartis Investigative Site Greenville South Carolina 29615
Novartis Investigative Site Mt. Pleasant South Carolina 29464
Novartis Investigative Site Summerville South Carolina 29485
Novartis Investigative Site Varnville South Carolina 29944
Novartis Investigative Site Fayetteville Tennessee 33734
Novartis Investigative Site Arlington Texas 76012
Novartis Investigative Site Austin Texas 78728-6904
Novartis Investigative Site Austin Texas 78735
Novartis Investigative Site Dallas Texas 75235
Novartis Investigative Site Houston Texas 77025
Novartis Investigative Site Houston Texas 77074
Novartis Investigative Site Houston Texas 77081
Novartis Investigative Site Houston Texas 77083
Novartis Investigative Site Lake Jackson Texas 77566
Novartis Investigative Site Pasadena Texas 77504
Novartis Investigative Site Plano Texas 75093
Novartis Investigative Site Richardson Texas 75080
Novartis Investigative Site St. George Utah 84790
Novartis Investigative Site Arlington Virginia 22203

Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.

Non-U.S. locations

This page focuses on the U.S. directory. The official record also lists 2 non-U.S. sites.

About this trial record page

What this page shows
Public field values for ClinicalTrials.gov record NCT01368536, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
What this page does not do
No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
Where the data comes from
Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
Last refresh
Last update posted Mar 20, 2013 · Synced May 6, 2026

Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.

Open the official record

The complete protocol, eligibility criteria, and contact information for NCT01368536 live on ClinicalTrials.gov.

View official ClinicalTrials.gov record →